Partillion Bioscience

About

Partillion Bioscience is a life science company based in Los Angeles, focusing on advanced single-cell assay technologies. The company is backed by venture partners like Initiate Studios and General Inception. It aims to enhance access to innovative single-cell tools for biomedical research through its proprietary Nanovial technology. The core offering of Partillion Bioscience is its nanovial platform, the first functional single-cell biology reagent platform. This technology allows for the isolation and analysis of individual cells using microscale test tubes compatible with standard lab equipment. It addresses industry challenges by enabling efficient screening and sorting of cells, particularly beneficial in antibody discovery. The company has also introduced an early-access program for a high-throughput multicell screening workflow, aiding scientists in localizing antibody-secreting cells and those expressing target proteins. Partillion has established partnerships with key players in the biotech sector, including Alloy Therapeutics, Inc., and is expanding its customer base internationally. The company secured $5 million in seed funding in late 2022 to support its growth and product development in functional single-cell analysis.